Research programme: transglutaminase inhibitors - Alvine Pharmaceuticals

Drug Profile

Research programme: transglutaminase inhibitors - Alvine Pharmaceuticals

Alternative Names: TG2 inhibitors - Alvine Pharmaceuticals; tTG inhibitors - Alvine Pharmaceuticals

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alvine Pharmaceuticals
  • Class Digestion aids
  • Mechanism of Action Transglutaminase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Coeliac disease

Most Recent Events

  • 07 Aug 2017 Early research in Coeliac disease in USA before August 2017 (Alvine Pharmaceuticals pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top